GH Research PLC (NASDAQ:GHRS) Shares Sold by Barclays PLC

Barclays PLC lowered its holdings in GH Research PLC (NASDAQ:GHRS) by 69.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,984 shares of the company’s stock after selling 13,925 shares during the period. Barclays PLC’s holdings in GH Research were worth $40,000 as of its most recent SEC filing.

Separately, Lynx1 Capital Management LP increased its position in shares of GH Research by 19.8% in the second quarter. Lynx1 Capital Management LP now owns 3,966,726 shares of the company’s stock worth $46,252,000 after acquiring an additional 656,163 shares in the last quarter. Hedge funds and other institutional investors own 56.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on GHRS. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of GH Research in a report on Friday. Canaccord Genuity Group lowered their price target on shares of GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a report on Monday, November 18th.

GH Research Trading Down 4.6 %

GHRS opened at $8.57 on Friday. The company has a fifty day simple moving average of $8.44 and a 200 day simple moving average of $9.20. The firm has a market cap of $445.88 million, a price-to-earnings ratio of -10.85 and a beta of 0.84. GH Research PLC has a twelve month low of $5.50 and a twelve month high of $14.99.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).